| 摘要: |
| 目的：研究肝喜片治疗晚期原发性肝癌的临床疗效。方法：回顾性收集103例湖南省中西医结合医院治疗的晚期原发性肝癌患者病例资料，将55例服用肝喜片的患者作为治疗组，48例服用复方斑蝥胶囊的患者作为对照组，2组治疗周期均为2个月。对比2组患者Karnofsky功能量表（KPS）评分、肿瘤标志物表达、肝功能水平、免疫因子表达、生存期及药物不良反应情况，并评价临床疗效。结果：总有效率治疗组为81.82%（45/55），对照组为60.41%（29/48），2组比较，差异有统计学意义（P<0.05）；2组KPS评分、肿瘤标志物表达及免疫因子表达治疗前后组内及治疗后组间比较，差异均有统计学意义（P<0.01）；2组肝功能水平治疗前后组内比较，差异有统计学意义（P<0.01），但治疗后组间比较，差异无统计学意义（P>0.05）；治疗组生存期长于对照组（P<0.05）；2组均未发生药物不良反应。结论：肝喜片能改善晚期肝癌患者肝功能，降低肿瘤标志物表达水平，提高患者免疫力与日常生活能力，并延长生存期。 |
| 关键词: 原发性肝癌 肝喜片 潘敏求 回顾性队列研究 |
| DOI： |
|
|
| Clinical effect of Ganxi Tablet in treatment of advanced primary liver cancer: A retrospective cohort study |
| CHEN Guanqing,PAN Bo,LI Yingchen |
| (Hunan University of Chinese Medicine，Changsha 410208，Hunan，China;Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine，Changsha 410006，Hunan，China) |
| Abstract: |
| Objective: To investigate the clinical effect of Ganxi Tablet in the treatment of advanced primary liver cancer.Methods: A retrospective analysis was performed for the clinical data of 103 patients with advanced primary liver cancer who were treated in Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine，among whom 55 patients received oral administration of Ganxi Tablet (treatment group) and 48 received oral administration of Compound Cantharidin Capsule (control group).The course of treatment was 2 months for both groups.The two groups were compared in terms of Karnofsky Performance Status (KPS) score，tumor markers，liver function，immune factors，survival time，and adverse drug reactions，and clinical outcome was assessed.Results: There was a significant difference in overall response rate between the treatment group and the control group ［81.82% (45/88) vs 60.41% (29/48)，P<0.05］.After treatment，both groups had significant changes in KPS score and the expression levels of tumor markers and immune factors，and there were significant differences in these indicators between the two groups after treatment (P<0.01).Both groups had a significant change in liver function after treatment (P<0.01)，but with no significant difference between the two groups after treatment (P>0.05).The treatment group had a significantly longer survival time than the control group (P<0.05).No adverse drug reaction was observed in either group.Conclusion: For patients with advanced primary liver cancer，Ganxi Tablet can improve liver function，reduce the expression levels of tumor markers，improve immunity and activities of daily living，and prolong survival time. |
| Key words: primary liver cancer Ganxi Tablet Pan Minqiu retrospective cohort study |
